Empagliflozin (EMPA)

DRUG5 trials

Sponsors

Mayo Clinic, National Taiwan University Hospital, University of Sao Paulo, Ain Shams University

Conditions

Bipolar DepressionBipolar DisorderBrugada Syndrome (BrS)Diabetes MellitusHeart FailureInsulin ResistanceNephropathy, DiabeticPancreatitis, Acute

Phase 2

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

RecruitingNCT06729996

Mayo ClinicDiabetes Mellitus, Pancreatitis, Acute, Pancreatitis, Chronic

Start: 2025-05-29End: 2027-05-31Target: 40Updated: 2026-04-03

Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome

Not yet recruitingNCT07146880

National Taiwan University HospitalBrugada Syndrome (BrS)

Start: 2025-09-15End: 2027-09-21Target: 10Updated: 2025-09-12

SGLT2 Adjunct in T1D

CompletedNCT07591077

Ain Shams UniversityNephropathy, Diabetic, Type 1 Diabetes

Start: 2024-11-20End: 2026-02-20Updated: 2026-05-18

the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

RecruitingNCT07692256

Ain Shams UniversityHeart Failure

Start: 2025-12-01End: 2027-02-01Target: 60Updated: 2026-07-09

Unknown Phase

Empagliflozin Adjunctive Therapy in Bipolar Depression

Not yet recruitingNCT07472920

University of Sao PauloBipolar Depression, Bipolar Disorder, Insulin Resistance

Start: 2026-03-09End: 2026-12-01Target: 20Updated: 2026-03-16